5th International Conference
Cancer Prevention 2008
St. Gallen, Switzerland
6-8 March 2008

This conference counts for:
15 ACOE CME credits hours (also accepted by AMA) or
15 ESMO-MORA credit points
Welcome and Session 1: Cancer prevention and health politics  
Chair: Peter Boyle, Lyon (FR) • Jack Cuzick, London (UK) • Hans-Joerg Senn, St. Gallen (CH)  

08.30 Welcome addresses  
  - Hans-Joerg Senn, St. Gallen/Switzerland for local organizers  
  - Jack Cuzick, London/UK for ISCaP (International Society of Cancer Prevention)  
  - Otis W. Brawley, Atlanta, GA/USA for ACS (American Cancer Society)  
  - Peter Indra, Berne/Switzerland for the Swiss Health Department  

Scientific program: Cancer prevention and health politics  
08.50 Do we make optimal use of the potential of cancer prevention? Peter Greenwald, Bethesda, MD/USA  
09.00 Why is it so difficult to transmit cancer prevention goals to society? Kate Law, London/UK for CRUK (Cancer Research United Kingdom)  
09.10 Possible predictors of successful cancer prevention programs Franz Porzsolt, Ulm/Germany  
09.20 Cancer prevention and the developing world: Mission impossible? Franco Cavalli, UICC, Bellinzona and Geneva/Switzerland  
09.30 Is cancer prevention ever going to be profitable? Thomas Szucs, Zurich/Switzerland  
10.00-10.30 Round-table-discussion (all moderators and speakers)  
10.00-10.30 Coffee break, posters I, exhibition  

Session 2: Cancer prevention: The scientific-epidemiological base  
Chair: Frank L. Meyskens, Irvine, CA/USA • Helmut Bartsch, Heidelberg/Germany  
10.30 The scientific basis of chemoprevention in humans: What’s important? Frank L. Meyskens, Irvine, CA/USA  
10.40 Cancer prevention: Scientific anticipations and clinical hopes David Sidransky, Baltimore, MD/USA  
11.00 Promises and limitations of biomarkers David F. Ransohoff, Chapel Hill, NC/USA  
11.20 Energy metabolism, cancer risk and cancer prevention Michael Pollak, Montreal, QC/Canada  
11.40 Discussion  
12.00 Keynote Lecture 1: The Cancer Prevention – Therapy Convergence  
Scott M. Lippman, Houston, TX/USA  
12.30-14.00 Lunch, posters I, exhibition  
13.15-14.00 ISCaP General Assembly  

Session 3: Cancer prevention, tobacco and nutrition  
Chair: Adriana Albini, Milano/Italy • Michael Pollak, Montreal QC/Canada  
14.00 Update of the European EPIC-Trial Elio Riboli, London/UK (invited)  
14.40 Angiopreventive properties of diet derivatives Adriana Albini, Milano/Italy  
15.00 Retinoids in breast cancer prevention Bernardo Bonanni, Milano/Italy  
15.15 Discussion  
15.30-16.00 Coffee break, posters I, exhibition  

Session 4: Cancer prevention, genetics and vaccines  
Chair: Thomas Cerny, St. Gallen/Switzerland • Christoph Huber, Mainz/Germany  
16.00 Cancer prevention and genetic testing: An update Judy Garber, Boston, MA/USA  
16.20 Use of cancer specific gene products for diagnosis and immunointervention Ugur Sahin, Mainz/Germany  
16.40 Cancer prevention by vaccination against Hepatitis B Mei-Hwei Chang, Taipei/Taiwan  
17.00 Cancer prevention and HPV John T. Schiller, Bethesda, MD/USA  
17.20 Discussion  
17.30 Welcome reception for all participants (conference venue)  
19.30 Faculty dinner in Restaurant “Schlössli am Spisertor” (by invitation)
Session 5: Cancer prevention and target organs I.: Breast cancer
Chair: Anthony Howell, Manchester/UK • Larry Wickerham, Pittsburgh, PA/USA

08.30 Introduction: Breast cancer prevention: Future avenues Anthony Howell, Manchester/UK
08.40 Tamoxifen orRaloxifene for chemoprevention of breast cancer in high risk women: The NSABP-experience Larry Wickerham, Pittsburgh, PA/USA
09.00 Use of aromatase inhibitors in breast cancer prevention Jack Cuzick, London/UK
09.20 Prevention of ER-negative breast cancer Powel H. Brown, Houston, TX/USA
09.35 Breast density and female hormone profiles Rudolf Kaaks, Heidelberg/Germany
09.50 Discussion
10.00-10.30 Coffee break, posters II, exhibition

Session 6: Cancer prevention and target organs II.: Digestive tract cancer
Chair: John Baron, Lebanon NH/USA • Florian Otto, St. Gallen/Switzerland

10.30 Introduction Florian Otto, St. Gallen/Switzerland
10.40 Update on the CAPP-2-trial (Aspirin and Starch) in HNPCC-risk individuals John Burn, Newcastle upon Tyne/UK
11.00 Prevention of Barrett’s esophagus + esophageal cancer in the ASPECT- and BOSS-trials Janusz Jankowski, Oxford/UK
11.20 Prevention of colorectal polyps by DFMO and Sulindac Daniel Pelot, Irvine CA/USA
11.40 Discussion
12.00 Keynote Lecture 2: CT-screening for lung cancer: The pros and cons Fergus V. Gleeson, Oxford/UK
12.30-14.00 Lunch, posters II, exhibition

Session 7: Cancer prevention and target organs III.: Prostate cancer
Chair: Fritz H. Schroeder, Rotterdam/The Netherlands • Hans-Peter Schmid, St. Gallen/Switzerland

14.00 Introduction Hans-Peter Schmid, St. Gallen/Switzerland
14.10 Review of best markers for prostate cancer Fritz H. Schroeder, Rotterdam/The Netherlands
14.30 Prevention of prostate cancer with Selenium and Vitamin E: SELECT-trial Leslie G. Ford, Bethesda MD/USA
15.05 The development of a cancer prevention research network Andrew G. Renehan, Manchester/UK
15.15 Discussion
15.30-16.00 Coffee break, posters II, exhibition

Session 8: Cancer prevention: Metabolic aspects; proffered papers/best abstracts and question forum
Chair: Ursula Kapp, St.Gallen/Switzerland • Frank L. Meyskens, Irvine, CA/USA

16.00 Metabolic aspects of cancer prevention Anthony Howell, Manchester/UK
16.15 Anti-angiogenic activity of a novel class of chemopreventive compounds, oleanolic acid terpenoids Ilaria Sogno, Milano/Italy
16.25 Effect of hyperhomocysteinemia on NMU-induced rat mammary tumorogenesis Tamara Pryzimirska, Kyiv/Ukraine
16.35 The effect of cabbage juice and its components on the expression and activity of phase 1 and 2 enzymes in rats Wanda Baer-Dubowska, Poznan/Poland
16.45 Cancer chemopreventive potential of apple juice – results of a short-term human intervention study with ileostomy patients Clarissa Gerhäuser, Heidelberg/Germany
16.55 - 17.30 Discussion and general questions forum about cancer prevention (all participants)
17.45 Bus departure to Restaurant Linde Teufen (from conference venue WBZ) for apéro
18.30 Appenzell buffet dinner with music (free for all participants)
22.00 Bus departure from Restaurant Linde, Teufen back to St. Gallen (Hotel Einstein and city center)
Sessions 9 and 10: Aspirin and NSAID’s in Cancer Prevention: Attempts of an International Consensus

Chairs: Jack Cuzick, London/UK • Peter Greenwald, Bethesda, MD/USA

08.30 Introduction into the consensus topic
Peter Greenwald, Bethesda, MD/USA

08.45 The fundamentals: How Aspirin and NSAID’s work
Michael Thun, Georgia, GA/USA

09.00 Aspirin and NSAID’s in prevention of colorectal cancers: The evidence
John Baron, Lebanon, NH/USA

09.15 Aspirin and NSAID’s in the prevention of breast and other cancers: The evidence
Powel Brown, Houston, TX/USA

09.30 Toxicity and long-term problems with Aspirin and NSAID’s: The problem
Frank L. Meyskens, Irvine, CA/USA

09.45 Coffee break, exhibition

10.15 Consensus finding roundtable: Panel discussion and evaluation of the evidence
(panellists and floor)
Chairs: Jack Cuzick, London/UK • Peter Greenwald, Bethesda, MD/USA
Panellists: speakers (above) and in addition:
John Burn, Newcastle upon Tyne/UK
Janusz Jankowski, Oxford/UK
Carlo LaVecchia, Milano/Italy
Florian Otto, St.Gallen/Switzerland
(incomplete)

12.15 Farewell

12.30 Adjourn

13.00 – 18.00 Excursions to Appenzell/Alpstein Mountains or Principality of Liechtenstein/Rhine Valley
(buses depart from conference venue and return to St. Gallen city)